S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
Log in
NASDAQ:DRNA

Dicerna Pharmaceuticals Stock Forecast, Price & News

$29.51
+0.63 (+2.18 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$27.88
Now: $29.51
$29.90
50-Day Range
$22.47
MA: $25.44
$28.88
52-Week Range
$11.75
Now: $29.51
$29.90
Volume1.91 million shs
Average Volume850,961 shs
Market Capitalization$2.21 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.33
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Dicerna Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097
Employees187
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.90 million
Book Value$2.22 per share

Profitability

Net Income$-120,460,000.00

Miscellaneous

Market Cap$2.21 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

162nd out of 1,969 stocks

Pharmaceutical Preparations Industry

74th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$29.51
+0.63 (+2.18 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

Is Dicerna Pharmaceuticals a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dicerna Pharmaceuticals stock.
View analyst ratings for Dicerna Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Dicerna Pharmaceuticals?

Wall Street analysts have given Dicerna Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dicerna Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Dicerna Pharmaceuticals
.

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced its earnings results on Thursday, February, 25th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by $0.60. Dicerna Pharmaceuticals had a negative net margin of 88.81% and a negative trailing twelve-month return on equity of 71.72%.
View Dicerna Pharmaceuticals' earnings history
.

How has Dicerna Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DRNA stock has increased by 74.8% and is now trading at $29.51.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for DRNA?

8 analysts have issued 12 month target prices for Dicerna Pharmaceuticals' shares. Their forecasts range from $33.00 to $45.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $37.13 in the next year. This suggests a possible upside of 25.8% from the stock's current price.
View analysts' price targets for Dicerna Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the following people:
  • Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 52, Pay $937.43k)
  • Dr. Bob D. Brown, Exec. VP of R&D and Chief Scientific Officer (Age 56, Pay $671.96k)
  • Dr. Ralf H. Rosskamp, Consultant (Age 68, Pay $707.13k)
  • Mr. Robert D. Ciappenelli M.B.A., Chief Commercial Officer (Age 54, Pay $339.51k)
  • Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
  • Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 74)
  • Mr. Douglas W. Pagan, Chief Financial Officer (Age 49)
  • Mr. James B. Weissman, Exec. VP & COO (Age 59)
  • Ms. Ling Zeng J.D., Chief Legal Officer & Sec.
  • Ms. Regina DeTore Paglia, Chief HR Officer

What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO?

35 employees have rated Dicerna Pharmaceuticals CEO Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among Dicerna Pharmaceuticals' employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Dicerna Pharmaceuticals' key competitors?

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD).

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.04%), Price T Rowe Associates Inc. MD (2.76%), Candriam Luxembourg S.C.A. (1.88%), Northern Trust Corp (1.11%), JPMorgan Chase & Co. (1.07%) and Renaissance Technologies LLC (0.92%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, Peter Kolchinsky and Regina M Paglia.
View institutional ownership trends for Dicerna Pharmaceuticals
.

Which institutional investors are selling Dicerna Pharmaceuticals stock?

DRNA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Russell Investments Group Ltd., Squarepoint Ops LLC, First Trust Advisors LP, ClariVest Asset Management LLC, Jane Street Group LLC, Price T Rowe Associates Inc. MD, and State of New Jersey Common Pension Fund D. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bob D Brown, James B Weissman, John B Green, and Regina M Paglia.
View insider buying and selling activity for Dicerna Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Dicerna Pharmaceuticals stock?

DRNA stock was purchased by a variety of institutional investors in the last quarter, including Caas Capital Management LP, BlackRock Inc., Panagora Asset Management Inc., Silverarc Capital Management LLC, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., Emerald Mutual Fund Advisers Trust, and Emerald Advisers LLC.
View insider buying and selling activity for Dicerna Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $29.51.

How much money does Dicerna Pharmaceuticals make?

Dicerna Pharmaceuticals has a market capitalization of $2.21 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Dicerna Pharmaceuticals have?

Dicerna Pharmaceuticals employs 187 workers across the globe.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Where are Dicerna Pharmaceuticals' headquarters?

Dicerna Pharmaceuticals is headquartered at 33 HAYDEN AVENUE, LEXINGTON MA, 02421.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.